[Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany].
In: Aktuelle Urologie, Jg. 51 (2020-06-01), Heft 3, S. 275-284
academicJournal
Zugriff:
Introduction: Androgen deprivation therapy (ADT) plays a pivotal role in the treatment of advanced or metastasised prostate cancer (PCa). The aim of this health services research was to compare real-world data on the initial use of different GnRH agonists and antagonists (GnRHa) with regard to prescription patterns, hospitalisation rates and costs.
Material and Methods: Anonymised claims data from > 70 German health insurance funds between 2010 and 2015 (n = 4 205 227) were analysed (1 year pre-observation period, 1 index quarter with initial GnRHa prescription, ≥ 2 years of follow-up (FU)).
Results: The study population included 2382 PCa patients (mean age 75 years). Leuprolide (Leu) was prescribed most frequently (56.6 %). At initial GnRHa administration, 70 % of patients neither had lymph node nor distant metastases. Around 11.2 % of all patients stopped GnRHa treatment after the first prescription, 17.6 % switched their initial therapy to another substance after a mean of 457 days (median: 399 days); in the hybrid (hyb) group 100 days earlier on average than in the agonist group (p = 0.016). The prevalence ranking of the most common comorbidities was consistent over time: hypertension, hyperlipidaemia, cardiovascular disease (CVD) and diabetes. The prevalence of hypertension increased significantly in the agonist group (16.4 %) compared with the antagonist (6.9 %, p = 0.022) and hyb group (11.6 %, p = 0.006). With regard to CVD, there were no significant differences in the relative growth rate between the 3 combined therapy classes. In total, 23.9 % of all patients died within the 3-year FU. The mortality rate was lowest for triptorelin (Trp, 22.1 %) and highest for goserelin (Gos, 29.4 %, n.s.). In the index quarter, 26.4 % of patients had at least one inpatient hospitalisation [min-max: Trp 22.4 %; Gos 30.3 %], with an average length of hospital stay/patient of 3 days [Trp 2.4; Gos 4.5]. The annual hospitalisation rate was between 36.2 and 40.7 %, the average length of hospital stay in the entire FU was between 17.6 (Trp) and 20.8 days (hyb). The average hospital costs in the index quarter were approx. EUR 1200 [Trp 988; Gos 1803] and per FU year approx. EUR 3000. In the Trp cohort, total costs (index quarter + 3 years) were more than EUR 1000 below the average costs of EUR 9476 [Trp 8116; Leu 9779; n.s.].
Conclusion: This comparative retrospective analysis provides real-world information on initial GnRHa treatment for advanced prostate cancer, revealing differences in treatment patterns, hospitalisation rates and hospital costs in Germany.
Competing Interests: Finanzierung: Diese Arbeit wurde von der Ipsen Pharma GmbH, München, Deutschland, unterstützt. MH: Reisekosten/Honorar von Ipsen. PH: Sprecher/Berater für Janssen, Ipsen, Takeda, and Sanofi. MK: keine. NK: keine. CC: Angestellte von Ipsen Pharma GmbH, München. AM: Sprecher/Berater für Astellas, BMS, Merck, Ferring, Roche, Janssen, Ipsen, Takeda, und Sanofi
(Owner and Copyright © Georg Thieme Verlag KG 2019.)
Titel: |
[Retrospective SHI (Statutory Health Insurances) real-world study on initial GnRH antagonist and agonist therapy for advanced prostate cancer: prescription patterns and hospital costs in Germany].
|
---|---|
Autor/in / Beteiligte Person: | Hupe, MC ; Hammerer, P ; Ketz, M ; Kossack, N ; Colling, C ; Merseburger, AS |
Zeitschrift: | Aktuelle Urologie, Jg. 51 (2020-06-01), Heft 3, S. 275-284 |
Veröffentlichung: | Stuttgart, Thieme, 2020 |
Medientyp: | academicJournal |
ISSN: | 1438-8820 (electronic) |
DOI: | 10.1055/a-1018-1651 |
Schlagwort: |
|
Sonstiges: |
|